Dare Bioscience Details $6M Offering: Warrants, Fees, and Lock-Ups

summarizeSummary

Dare Bioscience's 8-K details its $6M offering: 4.09M shares, 8.76M warrants, 7% placement fee, and a 60-day lock-up. The raise is vital given delisting and going concern risks.

check_boxKey Events · Financing and Capital Events · DARE

• Offering Structure Detailed

  4,085,687 shares at $1.37, 293,894 pre-funded warrants at $1.3699, and 8,759,162 common warrants (Series A and B) with $1.37 exercise price.

• Placement Agent Compensation

  Ladenburg Thalmann receives 7.0% cash fee (~$420k) plus warrants for 4.0% of shares sold at $2.12 exercise price, and up to $105k expense reimbursement.

• Lock-Up and Shareholder Approval

  Company and insiders subject to 60-day lock-up; shareholder approval for warrant exercise required within 90 days, with repeated meetings if needed.

• Registration Rights

  Company must file Form S-1 for resale of common warrant shares within 30 days and use best efforts to have it effective within 60 days.

auto_awesomeAnalysis · DARE · Life Sciences

Dare Bioscience filed an 8-K detailing the terms of its $6 million registered direct offering priced at $1.37 per share. The filing adds granular specifics: 4.09 million shares, 293,894 pre-funded warrants, and 8.76 million common warrants split between Series A and B. The placement agent receives a 7% cash fee plus warrants for 4% of shares sold at $2.12. The company also agreed to a 60-day lock-up and must seek shareholder approval for warrant exercise within 90 days. Against a backdrop of a Nasdaq delisting notice and going concern doubt, this capital raise is critical for near-term survival, but the warrant overhang and fees are substantial.